Complete Scientific Guide to Vitamin B12

Vitamin B12 is the only vitamin built around a metal. Its cobalt-centred structure is made by microbes, not by plants or animals, yet every human cell depends on it for DNA synthesis, red blood cell formation and nerve maintenance. Because the body stores only a few milligrams, and because absorption depends on a chain of proteins that can fail at several points, a shortfall can develop silently over years. This guide explains what the science firmly establishes about cobalamin, where evidence is thin or conflicting, and how to read supplement labels and clinical claims without over-reading them.

1. Executive Summary: Vitamin B12 (Cobalamin), B12 Absorption and B12 Deficiency

What it is. Vitamin B12, or cobalamin, is a water-soluble vitamin and a cobalt-containing cofactor for two human enzymes: methionine synthase and methylmalonyl-CoA mutase [1][4].

Why it matters. The vitamin supports one-carbon metabolism, DNA synthesis, normal red blood cell maturation, myelin maintenance and the breakdown of certain fatty acids and amino acids. Deficiency can cause megaloblastic anaemia and neurological injury, some of which may become irreversible if treatment is delayed [4][5].

Where it comes from. Only certain bacteria and archaea synthesize it. Humans obtain it from animal foods (meat, fish, dairy, eggs, shellfish, especially liver), fortified foods and supplements. Unfortified plant foods are not reliable sources [1][7].

Quick facts

Topic	Established position	Where the evidence is weaker
Function	Cofactor for methionine synthase and methylmalonyl-CoA mutase	Effects on mood, energy or cognition in people with adequate status
Forms	Cyanocobalamin, methylcobalamin, hydroxocobalamin, adenosylcobalamin	Claims that one supplemental form is universally superior
Intake reference (adults)	US RDA 2.4 µg/day; EU adequate intake 4 µg/day [2][3]	Optimal intake for older adults and special groups
Absorption	Intrinsic-factor-dependent (saturable) plus about 1% passive diffusion at high doses [4][5]	Precise absorption for individual products
At-risk groups	Older adults, vegans, people with pernicious anaemia, gastric or ileal disease, long-term metformin or acid-suppressant users [4][5][12][14]	Screening thresholds in asymptomatic people
Safety	No tolerable upper intake level set by the US Institute of Medicine [2]	Very high long-term intakes; observational cancer signals [18]
Treatment of deficiency	High-dose oral or intramuscular regimens are effective [6][9]	Which route is best for neurological deficiency

Established versus uncertain. The nutritional role, deficiency syndromes and the effectiveness of replacement in true deficiency are well established. Benefits of supplementation for cognition, cardiovascular outcomes or fatigue in people who are not deficient are not supported by the best available trials (see Sections 15 and 16) [15][17][24][25].

This guide is educational and is not medical advice. Suspected deficiency should be assessed by a qualified clinician.

2. Ingredient Definition and Identity

In strict chemical language, "cobalamin" refers to the cobalt-centred corrinoid framework with a particular lower ligand, 5,6-dimethylbenzimidazole, and a variable upper ligand. "Vitamin B12" is the nutritional name for the group of cobalamins that are biologically active in humans. In everyday use the two terms are interchangeable, although in laboratory and supplement settings "B12" is sometimes used loosely for cyanocobalamin specifically.

Water-soluble, yet stored. Vitamin B12 is classified as water-soluble, but it behaves unusually: the liver holds roughly 1–2 mg and total body stores are generally cited at 2–5 mg, enough to buffer intake interruptions for years [4][5]. This explains why deficiency in adults often appears gradually.

Role in normal physiology. Two reactions define its biochemistry. In the cytosol, methylcobalamin supports remethylation of homocysteine to methionine. In mitochondria, adenosylcobalamin supports conversion of L-methylmalonyl-CoA to succinyl-CoA [4]. Impairment of the first raises homocysteine and traps folate in a form cells cannot use well; impairment of the second raises methylmalonic acid (MMA).

Related compounds. Corrinoids that resemble cobalamin but lack the 5,6-dimethylbenzimidazole base, often called pseudovitamin B12 or cobalamin analogues, are produced by some bacteria, including cyanobacteria. They have limited or no activity in humans, and some may interfere with assays that rely on binding proteins [7]. This matters for interpreting claims about spirulina and some algae (see Section 4).

3. Botanical/Chemical Classification

Vitamin B12 is not a botanical ingredient. No plant makes it. Plants contain it only when contaminated with, or grown in the presence of, microbes or B12-containing soil and fertilizers, and the amounts are variable and generally unreliable [7].

Chemical class. Cobalamins are tetrapyrrole-derived corrinoids. The corrin ring resembles a porphyrin but lacks one methine bridge, which makes it smaller and more flexible. Four nitrogen atoms from the ring coordinate a central cobalt ion in the equatorial plane. A lower axial ligand (the dimethylbenzimidazole nucleotide tail) and an upper axial ligand complete the six-coordinate cobalt centre [21].

Coenzyme versus non-coenzyme forms. The two coenzyme forms in human cells are methylcobalamin (methyl upper ligand) and adenosylcobalamin (5'-deoxyadenosyl upper ligand). Cyanocobalamin (cyanide ligand) and hydroxocobalamin (hydroxyl ligand) are stabilized, non-coenzyme forms that cells convert to the active coenzymes through intracellular processing [8]. Aquocobalamin is closely related to hydroxocobalamin and occurs depending on pH.

Why this classification matters. Because cells convert incoming cobalamins to the same active products, form differences are less decisive than marketing sometimes suggests (see Section 8).

4. Origin, Cultivation and Source

Microbial biosynthesis

Vitamin B12 synthesis requires roughly 30 enzymatic steps and occurs only in some bacteria and archaea, via aerobic and anaerobic pathways that differ in when cobalt is inserted [5]. Ruminant animals obtain B12 from gut bacteria that synthesize it, then absorb it and store it in tissue and milk. Humans harbour B12-producing bacteria in the colon, but this synthesis occurs downstream of the ileal site where absorption takes place, so it is not considered a dependable supply [4].

Dietary sources

• Rich animal sources: liver and other organ meats, clams and other shellfish, fish, beef.
• Moderate sources: dairy products and eggs. Dairy B12 appears to be absorbed relatively well compared with some other foods [7].
• Fortified foods: breakfast cereals, plant-based milks, nutritional yeast and some meat analogues, where fortification is declared on the label.
• Algae and fermented foods: results are inconsistent. Many contain inactive corrinoid analogues, and a measured "B12" value by microbiological assay does not prove human activity [7].

Commercial production

Commercial vitamin B12 is produced almost entirely by fermentation of selected bacterial strains. Industrial strains have historically included Pseudomonas denitrificans and Propionibacterium freudenreichii, among others. Cobalt is supplied in the medium, and downstream steps convert and purify the cobalamin, commonly to cyanocobalamin, which is chemically robust [5]. Methylcobalamin and adenosylcobalamin are typically produced from these starting materials by conversion steps and are more light-sensitive.

Limits of plant sources

An adult who excludes all animal products without fortified foods or supplements is at documented risk of deficiency. A review of studies in vegetarians reported high deficiency prevalence by serum measures in several groups, with vegans at highest risk [22]. Reliable intake for these groups therefore relies on fortified foods or supplements.

5. History and Traditional Use

The vitamin's story begins with pernicious anaemia, a fatal disease in the nineteenth century. In 1926 George Minot and William Murphy reported that feeding large amounts of liver induced remission in patients, work that led to the 1934 Nobel Prize in Physiology or Medicine shared with George Whipple [19]. William Castle's work in the late 1920s indicated that an "extrinsic factor" in food required an "intrinsic factor" from gastric secretions, an insight that later explained why stomach disease causes deficiency [4].

In 1948 two groups, in the United States and the United Kingdom, independently crystallized the active red compound from liver [20]. Dorothy Hodgkin determined its three-dimensional structure by X-ray crystallography, published in 1956 and recognized by the 1964 Nobel Prize in Chemistry [21]. Total chemical synthesis was later achieved through the collaboration of the research groups of Robert Woodward and Albert Eschenmoser, in the 1970s. Industrial fermentation replaced liver extracts for supply.

Evolving clinical understanding

Historically, diagnosis centred on anaemia and was confirmed with absorption tests. Modern understanding recognizes that neurological complications can appear without anaemia, that serum B12 alone is an imperfect marker, and that deficiency has many causes beyond pernicious anaemia, including food-cobalamin malabsorption, medication effects and low intake [4][5][6].

Historical versus current practice

Crude liver extracts and routine injections for non-specific tiredness belong to historical practice. Current guidance is to confirm deficiency using clinical context and biomarkers, then select a treatment regimen to match cause and severity [6]. Traditional use in the sense of herbal systems does not apply, as B12 is a modern isolated nutrient.

6. Modern Nutraceutical Use

Today vitamin B12 appears in single-nutrient supplements, multivitamins, B-complex products, fortified foods and prescription preparations. Rationale for supplementation is strongest for groups with higher risk of deficiency: people eating no animal products, older adults with reduced gastric acid or atrophic gastritis, individuals with gastrointestinal surgery or disease affecting the stomach or terminal ileum, and long-term users of certain medications [1][4][5].

Food-bound versus free B12. Older adults with reduced acid secretion often absorb free (supplemental or fortified) B12 better than food-bound B12 because free B12 does not require acid and protease release. For this reason several authorities suggest that older adults meet needs from fortified foods or supplements [2].

Not a universal tonic. Marketing sometimes presents B12 as an energy booster. Controlled evidence does not show that people with adequate status gain energy from additional B12, and excess water-soluble vitamin is largely excreted (see Sections 15 and 16).

Nutrition versus treatment. A preventive dietary supplement is different from medical treatment of diagnosed deficiency. Treatment may involve loading doses, injections, monitoring of blood counts and neurological review, and investigation of the underlying cause. Self-treating suspected deficiency can delay diagnosis of conditions such as pernicious anaemia or bowel disease, so confirmation is advisable [6].

7. Chemical Composition

Cobalamins are large, polar, deep red crystalline molecules. They are soluble in water and sensitive to light, particularly the alkyl forms methylcobalamin and adenosylcobalamin, which photolyse to hydroxocobalamin.

Structural elements.

• A corrin macrocycle with seven amide side chains (three acetamide and four propionamide groups).
• A central cobalt ion that can exist in the +1, +2 and +3 oxidation states; the cobalt in B12 as supplied is Co(III).
• A nucleotide loop connecting the ring to the lower ligand, 5,6-dimethylbenzimidazole, which coordinates the cobalt in the "base-on" conformation.
• A variable upper ligand that defines the specific cobalamin.

Properties by form

Form	Upper ligand	Approximate molecular formula	Approximate molecular weight	Notes
Cyanocobalamin	Cyanide	C63H88CoN14O14P	about 1355	Most stable; widely used in supplements and fortification
Hydroxocobalamin	Hydroxyl	C62H89CoN13O15P	about 1346	Common injectable in several countries; long retention
Methylcobalamin	Methyl	C63H91CoN13O14P	about 1344	Active coenzyme; light-sensitive
Adenosylcobalamin	5'-deoxyadenosyl	C72H100CoN18O17P	about 1579	Active coenzyme; light-sensitive

Values are standard published approximations; confirm against a pharmacopoeial monograph or compendial source before quoting in regulated documents.

The differing masses are one reason label declarations are expressed in micrograms of cobalamin activity rather than molecular equivalence in some systems, and why labels should specify the form used.

8. Key Active Compounds

Methylcobalamin

A cytosolic coenzyme for methionine synthase. Supplements deliver methylcobalamin directly, but it is largely converted and redistributed in the body like other forms. It is more sensitive to light and heat than cyanocobalamin.

Adenosylcobalamin

The mitochondrial coenzyme for methylmalonyl-CoA mutase. It is available in some supplements, often combined with methylcobalamin. It is highly light-sensitive.

Hydroxocobalamin

A natural form that binds proteins well and is retained longer after injection than cyanocobalamin. It is widely used for injectable treatment in some countries, including the United Kingdom, and is also used in emergency toxicology for cyanide poisoning at much higher doses [6].

Cyanocobalamin

A stable, inexpensive, industrially produced form. The cyanide moiety is present in trace amounts (at typical supplement doses the cyanide released is very small and is normally detoxified, although it is a theoretical concern in advanced kidney disease). Most large trials and fortification programmes used cyanocobalamin.

Supplemental versus intracellular forms

After uptake via transcobalamin, cobalamins are released in lysosomes, the upper ligand is removed or processed (in the case of cyanocobalamin, by the CblC protein), and the cobalt centre is reconstituted into the two coenzymes [8]. Thus the form ingested need not match the active coenzyme.

Is any form superior?

A 2015 analysis argued that coenzyme forms are not likely to be superior to cyanocobalamin or hydroxocobalamin for preventing or treating deficiency, noting stability, cost and the extensive efficacy data on the latter [8]. Direct randomized comparisons by clinical outcome are limited. There may be niche situations, such as rare inherited disorders of cobalamin metabolism (for example cblC), where hydroxocobalamin is preferred and cyanocobalamin is less effective, but these are specialist settings. For the general reader, claims that one form is categorically better should be treated as unproven.

9. Extraction and Processing

Vitamin B12 is not extracted from plants. It is manufactured as follows, in general terms (details vary and are often proprietary):

1. Fermentation. Selected bacterial strains are grown in controlled media with a carbon source, nitrogen source and cobalt. Conditions such as oxygen, pH and the supply of the lower-ligand precursor influence yield.
2. Recovery. Cells are separated and cobalamins released, commonly by heat treatment at controlled pH.
3. Conversion. Cobalamins are converted to a single, stable form, commonly with cyanide, then purified using filtration, adsorption and crystallization.
4. Derivatization. Hydroxocobalamin, methylcobalamin or adenosylcobalamin are prepared by chemical or enzymatic conversion where required.
5. Formulation. Crystalline B12 is typically diluted into carriers because the active dose is microscopic; uniform blending is therefore a quality-critical step.

Stability. Light, extreme pH, reducing agents (including high-dose vitamin C in solution, according to some in-vitro work), heat and moisture may degrade B12 in certain formulations. Packaging in opaque containers and appropriate overage rules are common controls.

Documentation. Manufacturing routes differ among suppliers. A consumer or formulator should not assume a particular process or strain without documentation, such as a specification sheet and certificate of analysis (see Sections 10 and 23).

10. Standardization and Potency

Label declaration. In the United States, vitamin B12 is declared in micrograms and as percent Daily Value, where the Daily Value for adults is 2.4 µg [1]. Many supplements deliver amounts several hundred to several thousand times that value, which is allowed because there is no established upper limit and because absorption efficiency declines as dose rises.

Analytical methods. Typical methods include high-performance liquid chromatography with UV detection, liquid chromatography with mass spectrometry for form identification, and microbiological assays using organisms that depend on B12. Microbiological assays can overestimate human-active B12 if analogues are present, which is a recognized limitation for algae and some fermented foods [7].

Batch consistency and stability. Because dosing is tiny in mass terms, blend uniformity and content uniformity testing are key. Stability studies should show retention of the declared amount through the product's shelf life under labelled storage.

Content is not effect. The amount in a product does not equal the amount absorbed (see Section 13), and neither equals clinical benefit.

Certificates of analysis. A certificate of analysis lists tests performed, methods, specifications and results for a specified batch. It supports quality assessment only when the method is validated, the laboratory is competent and the batch number matches the product. It cannot replace clinical evidence of effect.

11. Mechanisms of Action

Two enzymes, two compartments

Vitamin B12 acts as a cofactor, not as a signalling molecule or antioxidant. Its established mechanisms centre on two enzymes [4]:

1. Methionine synthase (cytosol). Using methylcobalamin, the enzyme transfers a methyl group from 5-methyltetrahydrofolate to homocysteine, producing methionine and tetrahydrofolate. Methionine is then converted to S-adenosylmethionine, the major methyl donor for DNA, RNA, proteins, phospholipids and neurotransmitter metabolism.
2. Methylmalonyl-CoA mutase (mitochondria). Using adenosylcobalamin, the enzyme isomerizes L-methylmalonyl-CoA to succinyl-CoA, a step in the catabolism of odd-chain fatty acids, certain amino acids and cholesterol side chains.

Link with folate and one-carbon metabolism

Tetrahydrofolate generated by methionine synthase is needed to produce thymidylate and purines for DNA synthesis. When B12 is deficient, folate becomes "trapped" as 5-methyltetrahydrofolate, limiting nucleotide synthesis even if total folate is adequate. The result is impaired DNA replication, most visible in rapidly dividing cells such as bone marrow precursors, which produces large immature red cells (megaloblastosis) [4][5].

Biomarkers: homocysteine and methylmalonic acid

When methionine synthase falters, homocysteine accumulates. When methylmalonyl-CoA mutase falters, methylmalonic acid (MMA) accumulates. MMA is considered more specific for B12 status than homocysteine, because homocysteine also rises with folate or B6 deficiency, kidney disease and some genetic variants. MMA can also rise with reduced kidney function [4][6].

Neurological function

B12 deficiency can cause demyelination, peripheral neuropathy, subacute combined degeneration of the spinal cord and cognitive or psychiatric changes. The exact molecular pathway to nerve injury is not fully resolved. Proposals include impaired methylation of myelin components, accumulation of abnormal odd-chain fatty acids, altered cytokine and growth-factor signalling, and homocysteine-related toxicity. These explanations remain partly hypothetical [5].

Folate masking

High folic acid intake can correct the megaloblastic anaemia of B12 deficiency without correcting its neurological effects, potentially delaying diagnosis. This is a reason that clinicians check B12 status before treating anaemia with folic acid alone [2][4].

Established versus proposed effects

Mechanism or effect	Status
Cofactor for methionine synthase and methylmalonyl-CoA mutase	Established
Role in DNA synthesis and red cell maturation	Established
Prevention of deficiency-related neuropathy	Established for true deficiency
Lowering homocysteine	Established biochemical effect
Slowing cognitive decline or preventing vascular disease by lowering homocysteine	Not supported by most trials (Section 15)
Direct "neuroprotective" or "energy" effects beyond correcting deficiency	Proposed; limited human evidence

12. Pharmacokinetics

Release from food

In food, B12 is bound to proteins. Stomach acid and pepsin release it. In saliva and gastric juice it binds first to haptocorrin (also called R-protein or transcobalamin I). Reduced acid secretion, whether from atrophic gastritis, surgery or medication, can reduce release from food proteins, although free (supplemental) B12 is less dependent on this step [2][4].

Intrinsic factor and ileal uptake

In the duodenum, pancreatic proteases degrade haptocorrin, freeing B12 to bind intrinsic factor, a glycoprotein made by gastric parietal cells. The B12–intrinsic factor complex travels to the terminal ileum, where it binds the cubam receptor (cubilin with amnionless) on enterocytes and is taken up by endocytosis [4][5]. Loss of intrinsic factor, for example through autoimmune destruction of parietal cells in pernicious anaemia or gastrectomy, or damage or resection of the terminal ileum, markedly reduces absorption.

Plasma transport and cellular uptake

In the circulation, B12 is carried by two proteins. Transcobalamin delivers B12 to cells via the CD320 receptor; B12 bound to transcobalamin (holotranscobalamin) is the biologically available fraction and represents a minority of serum B12. Haptocorrin carries the majority of circulating B12 and is thought to be less available to most tissues [4][5]. Inside cells, lysosomal degradation releases the vitamin, and processing proteins convert it to the two coenzymes [8].

Storage, enterohepatic circulation and excretion

The liver stores most body B12. Cobalamin is secreted in bile, with estimates of several micrograms per day, and most is reabsorbed in the ileum. Efficient recycling slows depletion when intake is low but intact absorption exists. When absorption itself is defective, the recycling loop is also broken and stores deplete faster [4][5]. Excretion occurs through urine and faeces. Once transport proteins are saturated, excess absorbed vitamin is excreted renally [1].

Oral versus parenteral

Intramuscular or subcutaneous injection bypasses the gastrointestinal tract and delivers B12 directly to the circulation, producing high transient plasma levels, with a notable fraction excreted in urine soon after cyanocobalamin injection. Hydroxocobalamin binds plasma proteins more strongly and is retained longer, which supports less frequent maintenance schedules in some guidelines [6]. High-dose oral therapy relies on passive diffusion for a small fraction of the dose and is effective for many patients despite low fractional absorption [9][10].

13. Bioavailability

Definition. Bioavailability is the fraction of an ingested nutrient that is absorbed and available for use or storage. For B12 it depends on the form, the food or product matrix, the dose, and the person's digestive physiology [7].

Food-bound versus supplemental B12

At low intakes of around 1–2 µg per meal, healthy adults can absorb a substantial fraction of food B12, with commonly cited figures near one half under ideal conditions. Absorption efficiency declines as dose increases, because the intrinsic factor pathway saturates, generally cited as limiting active absorption to a few micrograms per sitting [1][4]. Individual foods differ: dairy B12 appears to be absorbed comparatively well, whereas absorption from some fish and egg preparations may be lower [7].

Passive diffusion at high oral doses

At high doses, roughly 1% of an oral dose is absorbed independent of intrinsic factor [1][4]. A 1,000 µg tablet therefore may supply on the order of 10 µg by this route, many times the RDA, which explains why high-dose oral therapy can correct deficiency even in pernicious anaemia, albeit with less certainty than injections in severe neurological presentations [6][9].

Factors that reduce absorption

• Age and atrophic gastritis: reduced acid and intrinsic factor secretion; estimates of food-cobalamin malabsorption in older adults vary widely by study [23].
• Gastrointestinal disorders and surgery: Crohn's disease, coeliac disease, small intestinal bacterial overgrowth, gastric bypass, gastrectomy and ileal resection [4][5][23].
• Medications: metformin, which can impair ileal absorption, and acid-suppressing drugs, which reduce release from food [12][13][14].
• Parasites and other causes: fish tapeworm infection (Diphyllobothrium latum) can compete for B12 [5].
• Nitrous oxide exposure: not an absorption problem but a direct functional inactivation of cobalamin, relevant in clinical and recreational use [4].

Dose absorbed versus dose retained

The administered dose, the absorbed dose and the amount retained in tissue are distinct quantities. Reported retention differs by route and form, and serum B12 concentration alone does not tell a clinician how much is functionally available to cells, which is why functional markers are sometimes added [6].

14. Preclinical Evidence Summary

What preclinical work shows. Cell culture studies, animal models and genetic experiments have been essential in defining B12 transport (intrinsic factor, transcobalamin, cubam), intracellular processing (the cbl complementation groups), and the two enzymatic roles [5][8]. Rodent and non-human primate models of B12 deficiency reproduce aspects of demyelination and haematological change, supporting the causal role of B12 in nervous system integrity.

Genetic disorders. Inherited defects in cobalamin metabolism, such as cblC disease, have clarified how failure of the processing pathway produces combined homocysteinuria and methylaciduria, and why some patients respond preferentially to hydroxocobalamin rather than cyanocobalamin [8].

Other laboratory findings. Cell and animal work has also suggested roles for B12 in epigenetic regulation, neuronal growth and inflammatory signalling. In addition, a 2015 study reported that B12 supplementation changed the gene expression of the skin bacterium Cutibacterium (Propionibacterium) acnes in a way that could promote acne in some people, an example of an unexpected microbial effect [26].

Limitations. Animal diets, doses and metabolic rates differ from humans. Many experiments used deficiency or pharmacological excess rather than typical intakes. Proposed benefits seen in cell models, such as neuroprotection, cannot be treated as proof of clinical effectiveness, and consistent translation to human outcomes in non-deficient people has not been shown.

15. Human Clinical Evidence Summary

Deficiency and haematological outcomes

Replacement in true deficiency reliably corrects the haematological picture. Reticulocyte response typically begins within days of starting effective treatment, and anaemia resolves over subsequent weeks, according to clinical guidelines [6]. This is the most robust clinical evidence for vitamin B12.

Oral versus intramuscular treatment

A Cochrane review of randomized trials comparing oral with intramuscular administration for deficiency in adults concluded that oral therapy at high doses appeared to achieve comparable serum B12 outcomes in the short term, but the evidence was limited by small numbers of trials and participants, and long-term clinical outcomes were not well covered [9]. Primary-care RCTs, such as one comparing oral regimens with injections, reported similar normalization of serum B12 [11]. A dose-finding trial in older people with mild deficiency estimated that oral cyanocobalamin doses in the region of 650–1,000 µg per day were needed to achieve maximal normalization of biomarkers [10].

Neurological outcomes

Neurological recovery is variable. Longer duration of symptoms before treatment tends to predict less complete recovery, which is why guidelines call for prompt treatment, and often parenteral initial therapy, when neurological involvement is present [5][6].

Cognition

In older adults, low B12 is associated with poorer cognition in observational research, but reverse causation and confounding limit interpretation. A Cochrane review of B12 for cognitive function found little reliable evidence of benefit [24]. A meta-analysis of eleven trials of homocysteine-lowering B vitamins (mostly folic acid with B12 and B6) found no significant effect on cognitive function or ageing-related decline [15]. The VITACOG trial found that a combination of folic acid, B12 and B6 slowed brain atrophy over two years in older adults with mild cognitive impairment, especially those with higher baseline homocysteine, but this combination design cannot isolate B12's contribution and it did not establish clinical prevention of dementia [16].

Cardiovascular outcomes

High homocysteine is associated with vascular disease in observational studies, yet randomized trials of homocysteine-lowering B vitamins have generally not reduced cardiovascular events [17][25]. This is a case where a biomarker responds to treatment without a corresponding benefit in clinical outcome.

Fatigue, mood and energy

Symptoms such as fatigue and low mood are common reasons for B12 testing and supplementation. In people with confirmed deficiency, treating the deficiency can improve related symptoms. Robust randomized evidence that B12 supplementation reduces fatigue or depressive symptoms in people with adequate status is, to my knowledge, lacking, and such uses should be considered unproven.

Deficiency in at-risk groups

Population research shows elevated deficiency rates in vegans, older adults and people on long-term metformin. In the Diabetes Prevention Program Outcomes Study, metformin use was associated with a higher risk of B12 deficiency and low B12 concentrations over time, and a randomized trial in type 2 diabetes reported a decline in B12 with metformin versus placebo [12][13]. A large case-control study linked long-term acid-suppressant use with increased risk of B12 deficiency [14].

Treatment of deficiency versus supplementation without deficiency

These are different questions. The first is well supported. The second shows consistent evidence of biochemical change (higher serum B12, lower homocysteine) but not of improved clinical outcomes in generally healthy people.

16. Evidence Grading by Outcome

Approach. Evidence is graded here qualitatively using the logic of the GRADE framework, which considers study design, risk of bias, inconsistency, indirectness, imprecision and publication bias, and which rates certainty as high, moderate, low or very low [34]. This table is an editorial summary based on the sources in Section 28, not a formal systematic GRADE assessment.

Outcome or claim	Population	Evidence direction	Certainty (qualitative)	Category
Prevents and treats megaloblastic anaemia from deficiency	People with deficiency	Benefit	High (long-established clinical effect)	Established
Prevents deficiency in vegans using fortified foods or supplements	Vegans and some vegetarians	Benefit	Moderate to high	Established nutritional role
High-dose oral therapy normalizes B12 status	Adults with deficiency	Comparable to injection for biochemical outcomes	Low to moderate	Evidence-supported
Neurological recovery with early treatment	Deficiency with neurological signs	Benefit, variable	Moderate (observational and clinical)	Evidence-supported
Reverses metformin- or PPI-associated low B12	Long-term users with deficiency	Treatment effective once deficient	Low to moderate	Evidence-supported
Improves cognition	Older adults without clear deficiency	No consistent benefit	Moderate that benefit is absent or small	Uncertain/unsupported [15][24]
Reduces cardiovascular events via homocysteine lowering	General or high-risk adults	No benefit	Moderate to high	Not supported [17][25]
Increases energy or reduces fatigue	People with adequate status	No reliable evidence	Very low	Unsupported
Methylcobalamin superior to cyanocobalamin	General population	Unproven	Very low	Unsupported [8]
Safety of high intakes over decades	General population	Mostly reassuring, observational cancer signals	Low	Uncertain [18]

17. Dosages Used in Studies

Dietary reference values

These values are intake recommendations for healthy people, not treatment doses.

Group	US RDA or AI (µg/day) [2]	EU adequate intake (µg/day) [3]
Infants 0–6 months	0.4 (AI)	Not set for this age band in the same form
Infants 7–12 months	0.5 (AI)	1.5 (from 7 months)
Children 1–3 years	0.9	1.5
Children 4–8 years	1.2	1.5 to 3.5 depending on age band
Children 9–13 years	1.8	3.5 to 4 depending on age band
Adolescents and adults	2.4	4
Pregnancy	2.6	4.5
Lactation	2.8	5

EU values vary by age band, so readers should confirm exact figures in the EFSA opinion [3]. India's ICMR-NIN recommendations (2020) also provide age-specific values and should be consulted directly for Indian dietary guidance [30].

Doses and regimens in research and clinical guidance

Context	Typical regimen reported	Route	Comparator and outcome measured	Source
Dose-finding in older adults with mild deficiency	Range of oral cyanocobalamin doses; roughly 650–1,000 µg/day estimated for maximal normalization	Oral	Placebo and lower doses; serum B12, holotranscobalamin, MMA, homocysteine	[10]
Primary-care deficiency	Oral regimens of about 1–2 mg daily vs standard injection schedule	Oral vs IM	Serum B12 normalization over months	[11]
Systematic review of routes	High-dose oral (about 1–2 mg/day) vs intramuscular	Oral vs IM	Serum B12 and symptoms; limited long-term data	[9]
Cognitive ageing trial	0.5 mg B12 with 0.8 mg folic acid and 20 mg B6 daily for 24 months	Oral	Placebo; brain atrophy rate and cognition	[16]
Clinical guideline, deficiency without neurological involvement	Hydroxocobalamin 1 mg intramuscularly in a loading schedule, then maintenance at intervals of about every 2–3 months	IM	Guideline recommendation	[6]
Clinical guideline, neurological involvement	More intensive loading schedule, then maintenance every 2 months	IM	Guideline recommendation	[6]

How to read these numbers

Doses used in research reflect specific populations and objectives. A trial dose for older adults with biochemical deficiency does not define an appropriate dose for a healthy adult or a person with a different cause of deficiency. The absence of a tolerable upper intake level does not equate to a recommendation to take large amounts. This guide does not provide a personalized dose; clinicians individualize doses by cause, severity, symptoms and monitoring results [6].

18. Timing and Use

General oral use. Free B12 in supplements is not bound to food proteins, so it does not require stomach acid for release in the way food B12 does. Studies have not established a single best time of day. Taking a supplement consistently is more important than the clock time.

With or without food. Evidence does not show a clear advantage either way for crystalline B12. Because intrinsic factor transport saturates at small amounts, a lower dose taken with meals or split across the day may use the active pathway more efficiently, whereas very high doses rely on passive diffusion irrespective of timing [1][4]. Practical differences have not been shown to matter clinically for most people.

Consistency and adherence. Maintenance requires continued intake, particularly where the cause persists (for example, a strict vegan diet or pernicious anaemia). Missed doses matter less in people with large stores but more in those with malabsorption and low reserves.

Oral, injectable and other regimens. Injectable schedules involve a loading phase followed by maintenance at intervals, because injected B12 delivers a large amount at once and is gradually used and excreted [6]. Oral schedules are daily. Which is preferable depends on the cause, severity, neurological involvement, adherence and patient preference.

Professional guidance. People with diagnosed deficiency, pernicious anaemia, bowel surgery, neurological symptoms, pregnancy or long-term medication use should have their regimen set and monitored by a qualified healthcare professional.

19. Available Forms

Format	Typical form of B12	Notes
Tablets and capsules	Cyanocobalamin most commonly; methylcobalamin and others available	Most studied oral route; widely available in multivitamins and B-complexes
Sublingual tablets, lozenges and sprays	Cyanocobalamin or methylcobalamin	Marketed as bypassing digestion; evidence does not show consistent superiority over swallowed high-dose tablets [9]
Liquids and drops	Various	Convenient for people who cannot swallow tablets; stability depends on formulation and storage
Fortified foods	Typically cyanocobalamin	Useful for vegans and older adults; check the label for declared amount
Injectable preparations	Hydroxocobalamin or cyanocobalamin, by region	Prescription or clinician-administered; used for deficiency, absorption disorders and severe presentations
Nasal and other prescription products	Cyanocobalamin	Available in some markets for specific indications

Differences among cobalamins

• Cyanocobalamin: stable, inexpensive, extensively studied.
• Methylcobalamin: active coenzyme, more light-sensitive; no consistent clinical advantage shown [8].
• Hydroxocobalamin: well retained after injection; used in injectable therapy in many countries [6].
• Adenosylcobalamin: active mitochondrial coenzyme; limited clinical trial data as a standalone supplement.

Practical considerations

Look for the specific form named on the label, the amount per serving in micrograms, opaque packaging for light-sensitive forms, the expiry date and storage guidance. Claims that sublingual or "active" forms are always better absorbed are not supported by consistent clinical evidence.

20. Safety and Side Effects

General profile

Vitamin B12 has a low toxicity profile. The US Institute of Medicine did not set a tolerable upper intake level, citing the low potential for adverse effects from food and supplements in healthy people [2], and the European Food Safety Authority likewise did not derive an upper level [3]. Oral supplements at doses far above the RDA have been used in trials for months to years without a consistent pattern of serious harm [9][10][16].

Reported adverse effects

• Skin reactions: acne-like or rosacea-like eruptions have been reported in some people taking high doses, and a possible microbial mechanism has been described in laboratory work [26].
• Hypersensitivity: rare allergic reactions, including itching, rash and, very rarely, anaphylaxis, mainly reported with injections and sometimes attributed to the cobalt-containing molecule, preservatives or excipients.
• Injection-related effects: pain at the injection site, headache, nausea or dizziness may occur.
• Early treatment effects: during initial treatment of severe megaloblastic anaemia, a rapid rise in blood cell production can lower serum potassium, and clinicians monitor for this. Treatment can also reveal an underlying polycythaemia vera in some patients.
• Optic neuropathy caution: labelling for some injectable cyanocobalamin products warns about use in people with Leber's hereditary optic neuropathy, where hydroxocobalamin is typically preferred.

Limits of the safety data

Most safety information comes from short- to medium-term trials and from populations of limited size. Observational studies have linked very high serum B12 with cancer and mortality, but this is usually interpreted as reflecting underlying disease (for example liver disease, myeloproliferative disorders or malignancy releasing B12-binding proteins) rather than supplement harm [5]. A prospective cohort (VITAL) reported higher lung cancer risk in men who took long-term high-dose B6 and B12 supplements, particularly smokers; because this was observational, it does not prove causation and has not been consistently replicated [18].

"No upper level" is not "risk-free"

The absence of a defined upper limit reflects limited evidence of harm, not proof of safety for every dose, product, duration or medical condition. Contaminated or mislabelled products, interactions with medical conditions (for example advanced kidney disease, where cyanide handling is a theoretical concern with cyanocobalamin), and injections given without medical assessment are separate considerations.

Safety versus the risk of untreated deficiency

Untreated B12 deficiency has well-documented risks, including anaemia and potentially irreversible neurological damage [4][5]. For people with deficiency or high risk of it, the realistic comparison is between the small risks of appropriate supplementation and the larger risks of leaving deficiency untreated.

When to seek medical evaluation

Persistent numbness or tingling, difficulty walking or balance problems, memory or mood changes, unexplained fatigue with pallor, a sore smooth tongue, or a diagnosed condition that affects absorption warrant assessment. Hives, facial swelling or breathing difficulty after a B12 dose requires urgent care.

21. Drug/Supplement Interactions

Interactions that change B12 status

These are effects of a medicine on absorption or levels, as opposed to a direct pharmacological interaction.

Medicine or exposure	Proposed mechanism	Evidence
Metformin	Reduced ileal absorption of the B12–intrinsic factor complex, possibly calcium-dependent	Randomized trial and trial follow-up show lower B12 and higher deficiency risk with longer use [12][13]
Proton pump inhibitors and H2-receptor antagonists	Lower acid and pepsin, reducing release of food-bound B12	Case-control evidence of higher deficiency risk with long-term use [14]
Nitrous oxide	Oxidizes the cobalt centre, inactivating methionine synthase	Established in clinical practice; can produce neurological injury, especially with repeated or prolonged exposure or pre-existing low B12 [4]
Bile acid sequestrants, neomycin and some other drugs	May bind or disrupt absorption	Reported mainly in drug labelling and smaller studies
Chronic heavy alcohol use	Gastrointestinal damage and poor intake	Associated with low B12 in observational research

Nutrient and supplement relationships

• Folic acid: supplemental folic acid can correct the anaemia of B12 deficiency while neurological injury progresses, so deficiency should be excluded or treated alongside it [2][4].
• Vitamin C: older in-vitro work suggested that large amounts of vitamin C might degrade B12 in solution. Evidence of a clinically important effect in people taking separate supplements is weak and inconsistent.
• Other B vitamins: B12 acts with folate and B6 in homocysteine metabolism, but combination effects are generally studied as multi-vitamin regimens [15][16].

Laboratory interpretation issues

• A recently taken high-dose supplement can raise serum B12 and obscure a deficiency during testing.
• Autoantibodies to intrinsic factor can interfere with some immunoassays, producing falsely normal or high serum B12 in pernicious anaemia [6].
• MMA and homocysteine are affected by kidney function and other nutrient deficits, so results require clinical context [4][6].
• Chloramphenicol, and treatments for other anaemias, can alter the expected haematological response to B12 treatment.

Professional review

People on long-term metformin, acid-suppressing medication, or undergoing treatment for deficiency should review monitoring and supplementation with their prescriber or pharmacist. Diabetes guidelines have recommended considering periodic B12 measurement in metformin users, especially those with anaemia or neuropathy [12].

22. Special Populations

Infants and children

Infants of mothers who are B12-deficient, including breastfed infants of mothers following unsupplemented vegan diets, are at risk of deficiency, with potentially serious developmental consequences. Recommended intakes rise with age (Section 17) [2][3].

Pregnancy and lactation

The US RDA is 2.6 µg in pregnancy and 2.8 µg during lactation [2]; EFSA sets adequate intakes of 4.5 and 5 µg respectively [3]. Maternal deficiency is associated in observational research with adverse pregnancy and infant outcomes, so prenatal care often includes attention to B12 status in at-risk women. Individual decisions on testing and supplementation belong with the obstetric care team.

Vegans and some vegetarians

Because unfortified plant foods do not provide reliable B12, authorities recommend fortified foods or supplements for vegans, and reviews of vegetarian populations report higher rates of low serum B12, especially in vegans [22][33]. Total intake should come from consistently used sources.

Older adults

Because atrophic gastritis and reduced acid are more common with age, the Institute of Medicine advised that adults over 50 meet the RDA mainly with fortified foods or supplements, whose free B12 does not depend on acid release [2]. Deficiency in older adults can present subtly, with cognitive, neurological or haematological changes [4][27].

Pernicious anaemia and GI conditions

Pernicious anaemia, an autoimmune loss of intrinsic factor, usually requires lifelong B12 replacement, with injectable or high-dose oral approaches chosen under medical supervision [6]. People who have had gastric or ileal surgery, including bariatric procedures, as well as those with Crohn's disease, coeliac disease or bacterial overgrowth, need monitoring because absorption may be impaired for life [5][32].

Medication-associated risk

Long-term metformin or acid-suppressant use increases risk (Section 21) [12][13][14].

Why evaluation differs by context

Testing commonly combines serum B12 with a functional marker, such as MMA or holotranscobalamin, plus a blood count and, when pernicious anaemia is suspected, intrinsic factor or parietal cell antibodies. Thresholds vary by laboratory and guideline; many guidelines treat serum B12 below roughly 150 pmol/L (about 200 pg/mL) as low and an intermediate band as needing a functional test [6][32]. Interpretation depends on symptoms, kidney function, pregnancy and other factors, which is why self-diagnosis is unreliable.

23. Quality, Testing and Authentication

Identity, potency, purity and stability. A high-quality B12 supplement should name the specific cobalamin form, state the micrograms per serving, and be supported by testing that confirms the declared content at release and through shelf life, plus testing for contaminants.

What documentation shows

• Certificate of analysis (CoA): batch-specific results for identity, assay (potency), microbial limits and, for finished products, heavy metals. A CoA is only informative if it specifies methods, the testing laboratory and the batch number.
• Validated methods: HPLC and LC–MS methods validated for specificity, accuracy and precision are preferred over generic assays that cannot distinguish forms.
• Good manufacturing practice (GMP): conformity with applicable GMP rules (for example, 21 CFR Part 111 in the United States) indicates documented controls over ingredients, process and records [29].
• Independent testing: programmes such as USP Verified and NSF certification test finished products against label claims and contaminant limits. Participation is voluntary and not every quality product is enrolled.
• Batch traceability and expiry: lot numbers and expiration dates allow recall, and storage conditions affect stability (Section 9).

Label interpretation

Check the form (cyanocobalamin, methylcobalamin, and so on), the amount per serving, percent Daily Value where listed, other ingredients, allergen statements, and instructions for storage. Be cautious of labels that make disease-treatment claims, which supplements should not make in most jurisdictions [29][28].

What certification cannot guarantee

Third-party certification can confirm that what is on the label is in the product and that specified contaminants are below limits. It does not demonstrate that the product works for a specific health outcome, and it does not replace clinical evidence or medical assessment.

24. Adulteration/Contamination Risks

Potential problems. Across the supplement industry, quality problems can include inaccurate potency (under- or over-fill), cross-contamination, microbial contamination, heavy metals or process residues, undeclared ingredients and inadequate stability. Vitamin B12's tiny effective mass makes uniform blending a notable manufacturing challenge (Section 10).

Poor manufacturing and storage. Exposure to light, heat and moisture degrades some forms, so poor storage in supply chains can reduce delivered potency. Injectable products require sterile manufacture, and products obtained outside regulated supply routes carry sterility and authenticity risks.

How testing and oversight help. Independent analytical testing, GMP inspection, adverse-event reporting systems and regulatory enforcement reduce uncertainty, though no system eliminates it.

Not all products are equal. Risks differ substantially between manufacturers. Generalizing that all B12 products or all processes carry the same risk would be inaccurate; assessment should rely on documentation and testing of the specific product.

25. Regulatory Overview

Regulations change. This section gives a general orientation, and readers should confirm current requirements with the official sources named below.

United States

Dietary supplements fall under the Dietary Supplement Health and Education Act of 1994. They do not need FDA approval before marketing, but manufacturers must follow current GMP rules (21 CFR Part 111), label accurately and avoid claims that a product treats or cures disease. Structure/function claims are permitted with a required disclaimer [29]. The adult Daily Value used on labels is 2.4 µg [1]. Injectable B12 is a prescription drug regulated under drug law.

European Union

Food supplements are governed by Directive 2002/46/EC, which restricts vitamin sources to positive lists, and health claims are governed by Regulation (EC) No 1924/2006. Authorized claims for vitamin B12 relate to normal energy-yielding metabolism, nervous system function, homocysteine metabolism, red blood cell formation, immune function, reduction of tiredness and fatigue, cell division and psychological function; they may be used only when conditions of use are met [28]. Maximum levels are set nationally rather than centrally. Permitted forms and conditions should be checked in the current legal annexes.

India

In India, the Food Safety and Standards Authority of India regulates health supplements, nutraceuticals and related products under its Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food regulations, which specify permitted ingredients, limits and labelling [31]. Injectable B12 medicines fall under drug regulation. The ICMR-NIN 2020 recommended dietary allowances provide national intake reference values [30].

Other jurisdictions

The United Kingdom, Canada, Australia and others have distinct frameworks for supplements and complementary medicines. Requirements for permitted forms, maximum doses and claims differ and should be read from the national regulator.

Supplements versus medicines

A food supplement is intended to supplement the diet and may not claim to treat disease. Prescription B12 injections are medicines used under clinical supervision. The same molecule can be regulated differently depending on dose, route and intended use.

26. Research Gaps

• Biomarkers and functional deficiency: how best to define deficiency in people with borderline serum B12, and how serum B12, holotranscobalamin, MMA and homocysteine should be combined, remain debated [6][32].
• Adequate baseline status: many supplementation trials include people with normal or unmeasured B12 status, which dilutes any possible effect and limits interpretation.
• Long-term outcomes: long-term trials of B12 alone, rather than in combination with folate and B6, for cognition, bone health, mood and neuropathy are limited [15][16].
• Route comparisons: better-powered, longer trials of oral versus injected therapy, especially in neurological deficiency and pernicious anaemia, are needed [9].
• Form comparisons: direct randomized comparisons of methylcobalamin, cyanocobalamin, hydroxocobalamin and adenosylcobalamin on clinical outcomes are scarce [8].
• Safety at high intakes: long-term safety of sustained very high doses, and the interpretation of observational cancer signals, need further study [18].
• Representation and standardization: trials should include older adults, diverse ethnic groups, pregnant women and people with absorption disorders, and use standardized outcome measures.

Promising questions should not be mistaken for conclusions: until stronger trials exist, benefits beyond correcting deficiency should be viewed as unproven.

27. FAQ

What is vitamin B12? A water-soluble, cobalt-containing vitamin made by microbes and needed for DNA synthesis, red blood cell formation and nervous system function (Sections 1–3).

What does vitamin B12 do in the body? It is a cofactor for methionine synthase and methylmalonyl-CoA mutase, linking it to homocysteine metabolism, folate use and fatty acid breakdown (Section 11).

Which forms of vitamin B12 are available? Cyanocobalamin, methylcobalamin, hydroxocobalamin and adenosylcobalamin, in tablets, capsules, sublingual products, liquids, fortified foods and injectables (Sections 8 and 19).

What are the main dietary sources? Animal foods such as liver, shellfish, fish, meat, dairy and eggs, plus fortified foods. Unfortified plant foods are not reliable (Section 4).

Who may be at risk of deficiency? Vegans, older adults, people with pernicious anaemia or gastrointestinal surgery or disease, and long-term users of metformin or acid-suppressing medicines (Section 22).

How is deficiency assessed? Usually by a blood count and serum B12, often with a functional marker such as MMA or holotranscobalamin, interpreted by a clinician in context (Section 22).

What is the difference between methylcobalamin and cyanocobalamin? Methylcobalamin is an active coenzyme form and cyanocobalamin is a stable form that the body converts. Evidence does not show that one is universally superior (Section 8).

What doses have been studied? Oral doses of around 1,000–2,000 µg daily have been used to treat deficiency, while dietary reference values for healthy people are only a few micrograms. Study doses are not personal recommendations (Section 17).

Is oral vitamin B12 effective? High-dose oral therapy normalizes B12 status in many people with deficiency, though evidence is limited in severe neurological cases (Sections 13 and 15).

What are the possible side effects? Rare skin reactions, hypersensitivity and injection-related effects. No upper limit has been set, but that is not a guarantee of safety in all situations (Section 20).

Can medicines affect vitamin B12 levels? Yes. Metformin and acid-suppressing drugs are associated with lower B12 status, and nitrous oxide inactivates the vitamin (Section 21).

How can consumers evaluate supplement quality? Check the declared form and amount, look for batch-specific testing, GMP compliance and independent verification, and remember that quality does not equal proven benefit (Sections 23 and 24).

When should someone seek medical advice? For numbness, balance or memory problems, unexplained fatigue or pallor, a known absorption disorder, pregnancy, or before starting long-term high-dose therapy (Section 20).

28. Scientific References

All entries are cited by author, year, journal and volume as best known. DOI and PubMed links should be added only after each record is verified directly in PubMed or at the publisher or issuing agency; none have been invented here.

1. National Institutes of Health, Office of Dietary Supplements. Vitamin B12: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
2. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academies Press; 1998.
3. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on Dietary Reference Values for cobalamin (vitamin B12). EFSA Journal. 2015;13(7):4150.
4. Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368:149–160.
5. Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017;3:17040.
6. Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166:496–513.
7. Watanabe F. Vitamin B12 sources and bioavailability. Exp Biol Med. 2007;232:1266–1274.
8. Obeid R, Fedosov SN, Nexo E. Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency. Mol Nutr Food Res. 2015;59:1364–1372.
9. Wang H, Li L, Qin LL, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 2018;(3):CD004655.
10. Eussen SJ, de Groot LC, Clarke R, et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Arch Intern Med. 2005;165:1167–1172.
11. Butler CC, Vidal-Alaball J, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. Fam Pract. 2006;23:279–285.
12. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101:1754–1761.
13. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.
14. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310:2435–2442.
15. Clarke R, Bennett D, Parish S, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr. 2014;100:657–666.
16. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5:e12244.
17. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med. 2010;170:1622–1631.
18. Brasky TM, White E, Chen CL. Long-term, supplemental, one-carbon metabolism–related vitamin B use in relation to lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. J Clin Oncol. 2017;35:3440–3448.
19. Minot GR, Murphy WP. Treatment of pernicious anemia by a special diet. JAMA. 1926;87:470–476.
20. Rickes EL, Brink NG, Koniuszy FR, Wood TR, Folkers K. Crystalline vitamin B12. Science. 1948;107:396–397.
21. Hodgkin DC, Kamper J, Mackay M, et al. Structure of vitamin B12. Nature. 1956;178:64–70.
22. Pawlak R, Lester SE, Babatunde T. The prevalence of cobalamin deficiency among vegetarians assessed by serum vitamin B12: a review of literature. Eur J Clin Nutr. 2014;68:541–548.
23. Allen LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull. 2008;29(2 Suppl):S20–S34.
24. Malouf R, Areosa Sastre A. Vitamin B12 for cognition. Cochrane Database Syst Rev. 2003;(3):CD004326.
25. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;(8):CD006612.
26. Kang D, Shi B, Erfe MC, et al. Vitamin B12 modulates the transcriptome of the skin microbiota in acne pathogenesis. Sci Transl Med. 2015;7:293ra103.
27. Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. BMJ. 2014;349:g5226.
28. European Union. Directive 2002/46/EC (food supplements); Regulation (EC) No 1924/2006 (nutrition and health claims); Commission Regulation (EU) No 432/2012 (list of permitted health claims). Check EUR-Lex for current consolidated texts.
29. United States. Dietary Supplement Health and Education Act of 1994; 21 CFR Part 111 (current good manufacturing practice for dietary supplements). Check FDA and eCFR for current texts.
30. Indian Council of Medical Research–National Institute of Nutrition. Nutrient Requirements for Indians: Recommended Dietary Allowances and Estimated Average Requirements. 2020.
31. Food Safety and Standards Authority of India. Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016, as amended. Check FSSAI for current texts.
32. Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. Am Fam Physician. 2017;96:384–389.
33. Rizzo G, Laganà AS, Rapisarda AMC, et al. Vitamin B12 among vegetarians: status, assessment and supplementation. Nutrients. 2016;8:767.
34. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.

29. Related Content / Product Bridge

Explore the supporting cluster

This pillar page is designed to connect to deeper articles. Internal links should be added once each cluster page is published, using descriptive anchor text such as:

• What Is Vitamin B12? Identity, Source and Supplement Use (identity and sources)
• How Vitamin B12 Works: Mechanisms of Action (methionine synthase, MMA and homocysteine)
• Vitamin B12 Human Clinical Research: What the Evidence Shows (deficiency, cognition, cardiovascular evidence)
• Vitamin B12 Dosage Research and Safe Use (dietary reference values and study regimens)
• Vitamin B12 Drug, Supplement and Food Interactions (metformin, acid suppressants, folic acid)
• How to Choose a High-Quality Vitamin B12 Supplement (buyer checklist)
• Vitamin B12 Scientific References and Clinical Study Library (references)

Educational information versus product choice

The sections above are educational and do not depend on any specific product. If you are considering a B12 supplement, the evidence-based questions to ask are: Is there a reason to suspect deficiency or increased risk? Does the label name the form and amount? Is there batch-level testing and independent verification? Is the claim on the label consistent with regulatory rules? Where a commercial product is later described in this section, it should be presented separately from the science, with its testing documentation available to readers, and without claims of treating or curing disease.

Next step

If you recognize any risk factor in this guide, such as a vegan diet, long-term metformin or acid-suppressing medication, digestive disease, or symptoms such as numbness or persistent fatigue, consider asking a healthcare professional about testing before choosing a supplement. If you already take B12, use the quality checklist in Section 23 to review your product.

Medical disclaimer: this article is for general education and does not replace advice from a qualified healthcare professional. Do not start, stop or change treatment for a diagnosed condition without medical guidance.